China quickly gaining preference over the US in biotechnology

Beijing-Prix of the US and China’s competition in artificial intelligence new studies indicate the rapid growth of China’s biotechnology, especially for drug development and agriculture.

Of the five critical technological sectors, “China has the most immediate opportunity to overtake the US in the field of biotechnology,” Harvard Bereffer’s Center for Science and International Affairs said on Thursday. “The Critical and New Technology Index“Covering II, biotechnology, semiconductor, space and quanta.

While the US is still a leader in all five, “a narrow gap in the US-China (in biotechnology) believes that future developments can quickly change the global balance of power,” the statement said.

The assessment repeats the increasing concern in Washington. In fact, the US National Security Commission on new biotechnology April ReportReferring to two years of research.

“There will be a moment for the Chatgpt biotechnology, and when China comes there, no matter how fast we run, we will never catch up,” the Congressional Bouquet Commission reported, citing a transformation chat released in the US.

“Our action window is closed. We need a two-story strategy: to make America innovatively faster and slowly in China,” the commission said. It recommends the US government to spend at least $ 15 billion over the next five years to support the internal biotechnology sector.

China’s biotechnology industry has developed to the US and European pharmaceutical giants over the past few months spent billions on acquire China developed in China Drugs This can treat cancer if commercialized with a regulatory approval. In March, the British Pharmaceutical Giant Astrazeneca announced it would be Invest $ 2.5 billion in the study and development center in Beijing.

Harvard Belfer Center noted that China’s strong biotechnological sides follow from “domination in pharmaceutical production and production”, except that they have more human talents than the US

China also has a “more flexible regulation mode and the ability to pull things faster,” said Synthya Tong, one of the authors of the Harvard report, in an interview with CNBC. She noted that the US usually has a longer approval process as well as a more extended period of research and development.

And just as China is developing its biotechnology sector, reports the US Beston Biotechnology Center and Boston dismissal and empty laboratories.

China has long been using perennial plans and overwhelming state policy to encourage key technology development. Biotechnal is no different Having received high -level support back in 2007.

“Currently, the US government does not have a cohesive, intentional biotech strategy, while China is gaining position due to its aggressive and carefully coordinated state initiatives,” the US Security Commission said.

Worried that just like Chinese restrictions on rare land Start to beat car manufacturersChinese domination in biotechnology can become another form of leverage for Beijing over the US and other countries.

“The likelihood there will cooperate (between) the United States and China, anything, very low, in some ways, at least in biotechnology and II,” from the Congress report, said Eric Rosenbach, Protect Director, new technologies and strategy program at the Belfer Harvard Center. He was the Chief of Staff of the US Department of Defense from 2015 to 2017.

He expects more pressure in the US on China.

It remains to know what it will mean in practice for business – although some say that the future of biotechnology development is inherently global.

According to the founder and CEO Alexandrova, the Insilico Medicine Medicine Medicine Medicine Medicine Medicine Medicine Medicine, which is distributed in China, North America and the Middle East, is counting on the world team. On Tuesday, the company announced the document in Nature Medicine what it was First, you will see a successful clinical testing with the help of a paired drug.

While AI Insilico’s work usually takes place in Canada and Abu Dababi, chemical trials and experiments are conducted in China, Kwarkov said, adding that the head of clinical development is in Boston. He refused to comment on the terms of commercialization in light of conversations with the regulators.

Other data show that China has surpassed the US in the number of clinical trials conducted, there is a significant increase in patents and can boast Most sciences about construction In the world.

The Chinese capital O Venture Partner Yang Fan, which previously worked in the pharmaceutical industry, said that the best biotechnology companies of the future would focus on the rules of different countries and use resources worldwide, unless it is profitable from arbitration capabilities that give different requirements and cost in different markets.

“The Chinese market is similar to a big supermarket for everything you can buy, AI or Biotechnology,” he said, adding that new startups in China should be “really good” to stand out. Since AI reduces innovation costs, the fan predicts that biotechnology is “the present moment Deepseek is likely to take place in five years.”